Q: GDRX What are your current thoughts on this company? Would it be a buy at this level? Thanks
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: If you were to invest in just one of these companies, which one would you choose and why?
-
AbbVie Inc. (ABBV)
-
Medtronic plc. (MDT)
-
Pfizer Inc. (PFE)
-
iShares U.S. Medical Devices ETF (IHI)
-
Vanguard Health Care ETF (VHT)
Q: Hi Group I am presently light on Health care (GUD - HMMJ - Doc) total is 2% of my portfolio) can you suggest a couple of etfs + Stocks to balance my portfolio . I believe health care is a must own sector do you agree Thanks for your guidance
Q: Hi, before you mentioned that we should keep small cap positions to around 3%. Ahead of WELL earnings, my WELL position is closing in on 5%. Is this reasonable or too aggressive? I can handle some volatility and I am a long term growth investor. I see in your growth portfolio WELL is over 5% now. Would you look to trim back to around 3% or maintain the 5% position? Thanks!
Q: Hi Guys!
Stepped into ABCL a couple months ago (1/2 position). Thinking about adding to it. What do think about it today?
Thanks
Dave
Stepped into ABCL a couple months ago (1/2 position). Thinking about adding to it. What do think about it today?
Thanks
Dave
Q: Hi,
I own TDOC and there is much "noise" today about Amazon entering the telehealth space and its all doom and gloom for TDOC.
I thought this news was actually "old news" in the sense that we did anticipate this was going to happen.
In your opinion, does this move by Amazon fundamentally change anything for TDOC?
Thanks,
I own TDOC and there is much "noise" today about Amazon entering the telehealth space and its all doom and gloom for TDOC.
I thought this news was actually "old news" in the sense that we did anticipate this was going to happen.
In your opinion, does this move by Amazon fundamentally change anything for TDOC?
Thanks,
Q: Looks like Abbvie is in talks to sell some of their drug lines acquired from Allergen. Can you comment on this and if it is a material impact to their business?
Q: Good morning,
Just wondering if DHT.UN will be paying a dividend and if so have they indicated how much?
Thanks
Just wondering if DHT.UN will be paying a dividend and if so have they indicated how much?
Thanks
Q: Retired, dividend-income investor. I am in the process of trimming my way out of Shaw (held in my TFSA) and looking at where to deploy the funds as they become available over time. I know WELL is not the same risk as SJR, but I am considering it.
However I really focus on asset allocation. I see WELL listed as Healthcare as well as Technology. Is it a hybrid? My tracking system has no problem with splitting it up into either or both sectors. As an example TC Energy, as a pipeline, is categorized as both a Utility as well as Energy. I believe it is a Utility, but because it seems to trade more like Energy stocks. I go 50-50.
I could do the same with WELL. What portion of their business is technology? Is any part of their business related to the Telecom sector? If I was forced to pick one sector, I'd go with Healthcare. Your thoughts?
Thanks....Steve
However I really focus on asset allocation. I see WELL listed as Healthcare as well as Technology. Is it a hybrid? My tracking system has no problem with splitting it up into either or both sectors. As an example TC Energy, as a pipeline, is categorized as both a Utility as well as Energy. I believe it is a Utility, but because it seems to trade more like Energy stocks. I go 50-50.
I could do the same with WELL. What portion of their business is technology? Is any part of their business related to the Telecom sector? If I was forced to pick one sector, I'd go with Healthcare. Your thoughts?
Thanks....Steve
Q: Can I have your view on Berkeley Lights. Seeing strong revenue growth, cash on hand. Perhaps positive cash flow and profitability over the next 18-24mths..
Q: Good morning, would you be able to comment on NovaBay Pharmaceuticals, do you see it as a stock worth picking up, and if you do, at what entry point would you yourself feel comfortable going in? I have been waiting for it to go lower but it seems to have a good bit of strength in the .90-$1.00 range. I was hoping it would dip into the .70s but its not looking like that will happen again soon. Thank you!!
Q: Can you comment on DR's latest quarter. I am looking for an exit time but I thought it had enough momentum to reach $9. Now I am not so sure. Appreciate you comments.
Q: Haven’t seen a question since January. MDRA looks over sold and the stock has just issued a possible early technical buy signal using scholastics. More importantly this mRNA technology got another “shot in the arm” with the latest data indicting that they may work by STOPPING transmission not just mounting an immune response to decrease the course f the disease while you remain contagious. How well funded is MRNA. How is their free cash flow and their debt load. This technology keeps getting more and more exciting. Malaria, the common cold, HIV, etc!! And if is better maybe even influenza?
For the science geeks: Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening
Aaron J Tande, MD, Benjamin D Pollock, PhD, MSPH, Nilay D Shah, PhD, Gianrico Farrugia, MD, Abinash Virk, MD, Melanie Swift, MD, MPH, Laura Breeher, MD, MPH, Matthew Binnicker, PhD, Elie F Berbari, MD Author Notes
Clinical Infectious Diseases, ciab229, https://doi.org/10.1093/cid/ciab229
Published: 10 March 2021
For the science geeks: Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening
Aaron J Tande, MD, Benjamin D Pollock, PhD, MSPH, Nilay D Shah, PhD, Gianrico Farrugia, MD, Abinash Virk, MD, Melanie Swift, MD, MPH, Laura Breeher, MD, MPH, Matthew Binnicker, PhD, Elie F Berbari, MD Author Notes
Clinical Infectious Diseases, ciab229, https://doi.org/10.1093/cid/ciab229
Published: 10 March 2021
Q: How come PFE is muddling along despite having one of the top covid vaccines? How much of their revenue/growth does it make up - or are they just too massive to it to move the needle? What's PFE's growth outlook and valuation?
Q: So working in the finance industry, when it comes to business valuation, I know private health clinics get very low multiples. If Well is continues to consolidate in a space where now one else is and provides technological efficiencies. Even if they are just able to capture the majority of market share in Canada, could the potential upside be the sky?
Q: What would your thoughts be on the dialogue health ipo? How would they compare with well health?
Thanks
Thanks
Q: Hi 5i,
Current shareholder of BMY for last 4 years and it simply has not done very much however pays small dividend of 3.2 %
I'm looking to sell and replace with something in same sector/space with better share price growth potential. Medium risk with 2- 3 year horizon. Dividend would be nice but not absolutely necessary.
Thx
Jim
Current shareholder of BMY for last 4 years and it simply has not done very much however pays small dividend of 3.2 %
I'm looking to sell and replace with something in same sector/space with better share price growth potential. Medium risk with 2- 3 year horizon. Dividend would be nice but not absolutely necessary.
Thx
Jim
Q: what can you tell me about this company.
i ask for 3 reasons;
cathie wood of ark keeps buying shares -what does she know that we do not.
also lloyd segals wife clarissa desjardins-he is ceo of repare sold her previous biotech for over 1 billion.
i know lightning never hits same spot twice.
also bristol myers seems to be heavily involved.
its cdn.-mtl based.
would you buy it.
dave
i ask for 3 reasons;
cathie wood of ark keeps buying shares -what does she know that we do not.
also lloyd segals wife clarissa desjardins-he is ceo of repare sold her previous biotech for over 1 billion.
i know lightning never hits same spot twice.
also bristol myers seems to be heavily involved.
its cdn.-mtl based.
would you buy it.
dave
Q: DOC closed a bought deal today at 2.70 in the face of a market price which is much lower now but was a bit above the deal pricing when announced. I assume the brokers and/or underwriters will want to recover the value of their investment but I do not know how this sort of event generally proceeds. Can you clarify please, including the role and obligations of the parties and the likely outcome for the share price. Thanks
Q: Do you see a reason for the fall of ISRG other than it was in the "expensive" stock category?